“Time is Brain”
This statement (Time is brain – Time is Brain) is actually the guiding principle of modern stroke care – but it is also increasingly cited in connection with immunotherapy in MS, even though the time
Continue reading
Category: MS Therapy
ECTRIMS 2018 – “Hit hard and early”
What is the correct therapy strategy for MS? This discussion was also in focus at this year’s ECTRIMS Meeting. Given the significant pathological changes and their associated effects on brain function, which are already present
Continue reading
MRI and Treatment Decision
I recently wrote on the topic of cortisone for MRI changes. The comments on the blog were so interesting that I wanted to pick them up and comment on them again.
Continue reading Cortisone for MR Changes?
I have often written about the role of MRI. In reality, I often experience a distinction problem between clinical stimulus and failure symptoms (= MS relapse) and changes in the MRI (new lesions).
Continue reading
… and what about secondary progressive Multiple Sclerosis?
However, this is a very valid question. Because in contrast to the “relatively” rare primary progressive MS (PPMS), most people with MS with a chronic progressive course belong to the group of secondary progressive MS.
Continue readingGilenya – Lymphocyte Levels in Clinical Practice
Lymphocyte levels also play an important role in monitoring the active substance Fingolimod (Gilenya). However, the considerations here are quite different from those for Dimethyl fumarate (Tecfidera – Lymphocyte levels in clinical practice from March
Continue reading
Cladribin – a new option for relapsing MS
On August 25, 2017, the European Medicines Commission EMA approved the active ingredient Cladribin under the trade name MAVENCLAD® for the treatment of relapsing multiple sclerosis (MS) in patients with high disease activity.
Continue reading
News from the AAN 2017
As a rule, I try to report on international congresses within the framework of DocBlog, which are particularly relevant for MS patients. Without a doubt, this includes the meeting of the American Academy of Neurology
Continue readingIntrathecal Cortisone Therapy
Cortisone is used in the treatment of acute MS relapses in Multiple Sclerosis. Usually, a high-dose cortisone preparation is administered intravenously over a period of 3 to 5 days. In addition, high-dose intravenous cortisone administration
Continue reading
Lymphocytopenia under Tecfidera
Dimethyl fumarate (Tecfidera®) has established itself as a first-line therapy for the treatment of multiple sclerosis. The availability of an effective oral therapy with a favorable side effect profile has expanded the possibilities of MS
Continue reading
